ArticleBMC cancer2025

Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study).

Annemarie Glöckner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.